Eloxx Pharmaceuticals, Inc. (ELOX) — SEC Filings
Eloxx Pharmaceuticals, Inc. (ELOX) — 7 SEC filings. Latest: 8-K (Aug 12, 2025). Includes 6 8-K, 1 SC 13D/A.
View Eloxx Pharmaceuticals, Inc. on SEC EDGAR
Overview
Eloxx Pharmaceuticals, Inc. (ELOX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Aug 12, 2025: Eloxx Pharmaceuticals, Inc. announced on August 6, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans.
Sentiment Summary
Across 7 filings, the sentiment breakdown is: 1 bearish, 6 neutral. The dominant filing sentiment for Eloxx Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Eloxx Pharmaceuticals, Inc. (ELOX) has filed 6 8-K, 1 SC 13D/A with the SEC between Jan 2024 to Aug 2025.
Filings by Year
Recent SEC Filings (7)
| Date | Form | Description | Risk |
|---|---|---|---|
| Aug 12, 2025 | 8-K | Eloxx Pharmaceuticals Reports Board and Compensation Changes | medium |
| Oct 17, 2024 | 8-K | Eloxx Pharmaceuticals Board Changes | medium |
| Aug 20, 2024 | SC 13D/A | Advent Life Sciences Amends Eloxx Pharma Stake | medium |
| Jul 16, 2024 | 8-K | Eloxx Pharmaceuticals Secures Funding via Convertible Notes | medium |
| Mar 29, 2024 | 8-K | Eloxx Pharmaceuticals Board Changes | low |
| Mar 14, 2024 | 8-K | Eloxx Pharmaceuticals Enters Material Definitive Agreement | medium |
| Jan 9, 2024 | 8-K | Eloxx Pharma Sells Unregistered Equity, Raising Capital |
Risk Profile
Risk Assessment: Of ELOX's 6 recent filings, 0 were flagged as high-risk, 5 as medium-risk, and 1 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Key Executives
- Dr. Jonathan G. Drachman
- Mr. David E. Johnson
- Dominic Schmidt
- Kaasim Mahmood
- Rajesh Parekh
- Shahzad Malik
- Dr. Jonathan G. W. Smith
- Dr. David E. Micklos
Top Tags
board-change (2) · management (2) · management-change (1) · compensation (1) · amendment (1) · ownership-change (1) · sec-filing (1) · financing (1) · debt (1) · convertible-notes (1)
Frequently Asked Questions
What are the latest SEC filings for Eloxx Pharmaceuticals, Inc. (ELOX)?
Eloxx Pharmaceuticals, Inc. has 7 recent SEC filings from Jan 2024 to Aug 2025, including 6 8-K, 1 SC 13D/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ELOX filings?
Across 7 filings, the sentiment breakdown is: 1 bearish, 6 neutral. The dominant sentiment is neutral.
Where can I find Eloxx Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Eloxx Pharmaceuticals, Inc. (ELOX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Eloxx Pharmaceuticals, Inc.?
Financial highlights for Eloxx Pharmaceuticals, Inc. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for ELOX?
Investment thesis data for ELOX will be available once enriched filings are processed.
Who are the key executives at Eloxx Pharmaceuticals, Inc.?
Key executives identified across Eloxx Pharmaceuticals, Inc.'s filings include Dr. Jonathan G. Drachman, Mr. David E. Johnson, Dominic Schmidt, Kaasim Mahmood, Rajesh Parekh and 3 others.
What are the main risk factors for Eloxx Pharmaceuticals, Inc. stock?
Of ELOX's 6 assessed filings, 0 were flagged high-risk, 5 medium-risk, and 1 low-risk.
What are recent predictions and forward guidance from Eloxx Pharmaceuticals, Inc.?
Forward guidance and predictions for Eloxx Pharmaceuticals, Inc. are extracted from SEC filings as they are enriched.